JANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTSPRNewsWire • 07/12/24
JanOne Announces Plan to Enhance Stockholder Value Through Strategic RealignmentPRNewsWire • 07/10/24
JanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 SigmaPRNewsWire • 06/26/24
ALT5 SIGMA, A JANONE COMPANY, ADDS PREPAID VISA®️ CARD INTEGRATION TO ALT5 SETTLEMENT PLATFORMPRNewsWire • 06/25/24
JanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024PRNewsWire • 06/13/24
ALT5 Sigma, a wholly-owned subsidiary of JanOne, Launches ALT5 Settlement Platform aimed at the untapped $27.3 Billion Global Digital Content Creation MarketPRNewsWire • 06/11/24
ALT 5 Sigma, a wholly-owned subsidiary of JanOne to Present at the iFX Expo, the World's largest online trading conference and tradeshowPRNewsWire • 05/28/24
JanOne Closes Acquisition of ALT 5 Sigma Inc., a Leading Next Generation Blockchain FintechPRNewsWire • 05/16/24
JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment ConferencePRNewsWire • 08/31/23
JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic PainPRNewsWire • 08/29/23
JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual MeetingPRNewsWire • 08/25/23
JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq RulesPRNewsWire • 08/22/23
JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq RulesPRNewsWire • 08/18/23
JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual MeetingPRNewsWire • 08/18/23
JanOne files international patent application for methods of using low dose naltrexone to treat chronic painPRNewsWire • 06/28/23
JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023PRNewsWire • 04/13/23
JanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-MarketPRNewsWire • 03/24/23
JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management TeamPRNewsWire • 03/23/23
JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-MarketPRNewsWire • 03/23/23